Skip to main content

Table 1 Demographic table of study collective and correlation analysis between relapse compartment and clinicopathological variables from primary PDAC; n = 141

From: Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy

  No metastases
n = 54
Hepatic, n = 43 Pulmonary, n = 17 Local, n = 28 p-value
Age in years
 Median (range) 68 (17–95) 69 (46–86) 64 (41–81) 63.5 (42–88) 0.521
Gender      0.109
 Female 27 19 8 11  
 Male 27 24 9 17  
Tumor localisation      0.265
 Pancreatic head 45 42 16 25  
 Pancreatic tail 9 1 1 3  
T-stage      0.478
 T1 8 2 1 2  
 T2 26 27 9 20  
 T3 20 13 7 5  
 T4 0 1 0 1  
N-stage      0.157
 N0 17 6 3 6  
 N1 33 31 14 22  
 N2 4 6 0 0  
Grading      0.446
 G1/G2 33 25 8 19  
 G3 21 18 9 9  
Pn      0.483
 Pn0 15 7 5 5  
 Pn1 36 33 12 20  
 Missing 3 3 0 3  
L      0.161
 L0 34 20 6 14  
 L1 17 20 11 11  
 Missing 3 3 0 3  
V      0.011
 V0 41 23 15 22  
 V1 10 17 2 3  
 Missing 3 3 0 3  
Resection status      0.305
 R0CRM− 49 39 14 21  
 R1/R0CRM +  5 4 3 7  
Chemotherapy      0.692
 MD regime 14 8 3 7  
 FOLFIRINOX 3 6 1 1  
 Gemcitabine mono 30 29 9 15  
 No CTx 7 0 4 5  
  1. Only venous invasion correlated with metachronous hepatic metastases. Pearson Test and Mann–Whitney U test were used to test for statistical significance. p-value ≤ 0.05 indicates significance
  2. CTx chemotherapy, MD multidrug, Pn perineural invasion, L: lymphatic invasio, V venous invasion